Compare AAME & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AAME | GRML |
|---|---|---|
| Founded | 1968 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 29.2M |
| IPO Year | 1995 | 2022 |
| Metric | AAME | GRML |
|---|---|---|
| Price | $1.31 | $9.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.9K | ★ 16.7M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.91 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $1.25 | $0.16 |
| 52 Week High | $3.24 | $18.21 |
| Indicator | AAME | GRML |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.64 |
| Support Level | N/A | $0.53 |
| Resistance Level | N/A | $11.66 |
| Average True Range (ATR) | 0.00 | 2.25 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 0.00 | 46.68 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.